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The inflammatory responses in Alzheimer’s disease (AD)
and prion-related encephalopathies (PRE) are dominated
by microglia activation. Several studies have reported that
the amyloid-beta (Ab) peptides, which are associated with
AD, and the pathogenic isoform of prion protein (PrPSc)
have a crucial role in neuronal death and gliosis that occur
in both of these disorders. In this study, we investigate
whether Ab and PrPSc cause microglia activation per se
and whether these amyloidogenic peptides differentially
affect these immunoeffector cells. In addition, we also
determined whether substances released by Ab- and PrP-
activated microglia induce neuronal death. Cultures of rat
brain microglia cells were treated with the synthetic pepti-
des Ab1–40, Ab1–42 and PrP106–126 for different time periods.
The lipopolysaccharide was used as a positive control of
microglia activation. Our results show that Ab1–40 and
PrP106–126 caused similar morphological changes in micro-
glia and increased the production of nitric oxide and hydro-
peroxides. An increase on inducible nitric oxide synthase
expression was also observed in microglia treated with
Ab1–40 or PrP106. However, these peptides affected in a dif-
ferent manner the secretion of interleukin-1b (IL-1b) and
interleukin-6 (IL-6) secretion. In cocultures of microglia-neu-
rons, it was observed that microglia treated with Ab1–40 or
PrP106–126 induced a comparable extent of neuronal death.
The neutralizing antibody for IL-6 significantly reduced the
neuronal death induced by Ab- or PrP-activated microglia.
Taken together, the data indicate that Ab and PrP peptides
caused microglia activation and differentially affected cyto-
kine secretion. The IL-6 released by reactive microglia
caused neuronal injury. VC 2006Wiley-Liss, Inc.
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Microglia are the immunocompetent cells of the
CNS, playing an important role in brain homeostasis
maintenance. These cells are very sensitive to changes in
the surrounding environment and readily become acti-
vated in response to infection or injury (Streit, 2002; Liu
and Hong, 2003). Microglia activation is a gradual proc-
ess, involving cell proliferation and migration to the site
of injury, as well as morphological and functional
changes. Activated microglia have an amoeboid mor-
phology, up-regulate several surface receptors, and secrete
a large variety of soluble factors, such as cytokines, che-
mokines, proteases, reactive oxygen species (ROS), and
nitric oxide (NO; Lee et al., 2002; Davalos et al., 2005).
Although some of these factors promote neuronal and
glial survival, most are neurotoxic and proinflammatory
(Liu and Hong, 2003; van Rossum and Hanisch, 2004).
Thus, it is widely accepted that microglia activation pro-
vides an initial protective role, whereas a persistent acti-
vation of these cells and the consequent sustained secre-
tion of inflammatory factors contribute to neuronal
death that occurs in neurodegenerative diseases.
Prion-related encephalopathies (PRE) and Alzhei-
mer’s disease (AD) are neurodegenerative disorders char-
acterized neuropathologically by the presence of extrac-
ellular amyloid deposits, extensive neuronal loss, and
gliosis. In AD, the amyloid deposits are composed of
amyloid-beta (Ab) peptides (40–42 amino acids), which
result from the abnormal proteolytic cleavage of amyloid
precursor protein, whereas, in PRE, the amyloid depos-
its are constituted mainly of the scrapie isoform of prion
protein (PrPSc), a conformational variant of the cellular
prion protein (PrPC). The amyloid deposits are generally
colocalized with reactive microglia, inflammatory factors,
and dystrophic neurites (Nelson et al., 2002; Liu and
Hong, 2003). Increasing evidence suggests that microglia
activation is concomitant with Ab and PrPSc deposition
and precedes neuronal death (Marella and Chabry, 2004;
Veerhuis et al., 2005). Indeed, microglia are considered
to be involved in neuroinflammation and, consequently,
in the progression of AD and PRE (Eikelenboom et al.,
2002; Veerhuis et al., 2005).
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In the present study, we analyzed whether Ab and
PrP differentially activate microglia cells and whether
microglia treated with these peptides trigger neuro-
nal death. The synthetic peptides Ab1–40, Ab1–42, and
PrP106–126, which are widely used to mimic the effect of
Ab and PrPSc, were utilized to stimulate cultured rat
brain microglia cells. Morphological changes and molec-
ular responses induced by these peptides in microglia
cells were determined and compared with microglial
reactions to lipopolysaccharide (LPS), a well-known in-
ductor of inflammation. Cocultures of microglia/neurons
were used to investigate whether the substances released




Neurobasal medium and B-27 supplement were pur-
chased from Gibco (Paisley, United Kingdom). Synthetic peptides
of Ab and PrP were from Bachem (Bubendorf, Switzerland).
The rat anti-ED1 (clone ED1), rabbit anti- inducible nitric ox-
ide synthase (iNOS; clone pAb), and rat anti-interleukin-6 (IL-
6) antibodies were obtained from Serotec (Oxford, United
Kingdom), BD Biosciences (Erembodegem, Belgium), and R&D
Systems (Minneapolis, MN), respectively. Alexa Fluor IgG con-
jugated secondary antibodies, 20,70-dichlorofluorescin diacetate,
Amplex red hydrogen peroxide/peroxidase assay kit (A-22188),
and Hoechst 33342 were acquired from Molecular Probes (Lei-
den, The Netherlands). The fluorescent mounting medium was
from DakoCytomation (Glostrup, Denmark). ELISA kits for rat
interleukins were obtained from R&D Systems (Abingdon, United
Kingdom). Millicell culture plate inserts were from Millipore
(Bedford, MA). Reagents and apparatus used in immuno-
blotting assays were obtained from Bio-Rad (Hercules, CA),
whereas PVDF membranes, alkaline phosphatase-linked anti-
mouse secondary antibody, and the enhanced chemifluores-
cence (ECF) reagent were from Amersham Biosciences (Buck-
inghamshire, United Kingdom). Percoll solution was also pur-
chased from Amersham Biosciences. All other reagents, includ-
ing LPS (Escherichia coli O26:B6), were from Sigma Chemical
Co. (St. Louis, MO).
Microglia Cell Cultures
Primary microglial cell cultures were obtained from
neonatal Wistar rats 5–7 days old, according to the method
described by Kingham and colleagues (1999), with some mod-
ifications. In brief, after cervical dislocation and decapitation
of rats, the brains were removed and placed in ice-cold phos-
phate buffer solution [PBS (in mM) 140 NaCl, 4 KCl, 8.5
KH2PO4, 7.4, Na2HPO4, pH 7.4]. After removal of the cere-
bellum, they were cut into small pieces and homogenized.
The brain homogenate was then centrifuged at 500g for
10 min at 48C. The pellet was resuspended in a 70% Percoll
solution. The 70% Percoll-cell mixture was then overlaid with
35% Percoll and finally with PBS. The Percoll gradient
formed was centrifuged at 1,300g for 45 min at 208C, and the
microglia cells were collected at the 35%/70% interface. Then,
the cells were mechanically dissociated, through a 5-ml glass
pipette, and washed in PBS (five times the cell volume col-
lected) at 500g for 10 min at 208C. Dissociated microglia cells
were ressuspended in astrocytes conditioned medium (ACM)
and counted in a hemocitometer. The ACM was obtained
from rat brain astrocytes cultured in DMEM medium supple-
mented with 10% fetal calf serum and penicillin (100 U/ml)
and streptomycin (100 lg/ml; Sastradipura et al., 1998). The
microglia cells were cultured in filtered ACM (pH 7.4) at
378C in an atmosphere containing 95% air and 5% CO2. The
cells were plated in plastic plates or in cell culture inserts
(membrane pore size 0.4 lm) at a density of 0.2 3 106 cells/
cm2 or in glass coverslips at 0.1 3 106 cells/cm2. Twenty-four
hours after plating, the medium was changed and the cells
were treated with the peptides or LPS for different periods of
time. The morphological analysis and immunoreactivity to-
ward microglial marker complement receptor type 3 using
anti-CD11b monoclonal antibody (1:50; Serotec) and anti-
glial fibrillary acid protein (GFAP) polyclonal antibody (1:200;
DakoCytomation) had shown that these cultures are consti-
tuted of >95% microglia (data not shown).
Neuron-Microglia Cocultures
Primary cultures of cortical cells were prepared from
15–16-day embryos of Wistar rats according to the method
described by Agostinho and Oliveira (2003). Cortical cells
were cultured in Neurobasal medium with 2 mM L-gluta-
mine, 2% B27 supplement, penicillin (100 U/ml), and strepto-
mycin (100 lg/ml). The neurons were plated on poly-L-ly-
sine (0.1 mg/ml)-coated coverslips at a density of 0.6 3 106
cells/cm2 and maintained at 378C in a humidified atmosphere
of 5% CO2/95% air. Microglia cells cultured in inserts, for
1 day, were placed into the wells containing the neurons, with
5 days in culture. These cocultures were maintained in ACM
medium, and the treatment with the peptides or with LPS
started 16 hr afterward. The distance between the microglia
(inserts) and neurons (coverslips) was approximately 1 mm.
Treatment With Peptides
Cultured microglia cells were treated with Ab1–40 or
Ab40–1 (5 lM), Ab1–42 (0.5 lM), PrP106–126 (25 lM), and
scrambled PrP (25 lM) for different periods ranging from
3 to 24 hr, as indicated in the figure legends. The peptides
were added into culture medium at the second culturing day.
The peptides were reconstituted according to the manufac-
turer’s instructions, and Ab1–40 or Ab40–1 peptides were aged
in PBS buffer, in a stock concentration of 231 lM, for 7 days
at 378C to obtain fibrillar Ab. LPS (0.1 lg/ml) was added to
cultured microglia as indicated for peptides. Cells not treated
(control) or treated with 2.1% PBS (vehicle control) were
used as controls.
Immunocytochemistry
Microglia cells cultured in glass coverslips were treated
with peptides or LPS. Then, the cells were washed with PBS
and fixed with a 4% paraformaldehyde solution (pH 7.4) for
30 min at room temperature (RT). The cells were permeabil-
ized with PBS-0.2% Triton X-100 for 2 min at RT, and
blocked with 0.1% bovine serum albumin (BSA) in PBS
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before incubation with a primary antibody for 1 hr at RT.
The anti-ED1 (1:500) and anti-iNOS (1:500) monoclonal
antibodies was used to recognize an antigen predominant in
activated microglia and iNOS, respectively. After being
washed in PBS to remove the unbound antibody, they were
incubated with labelled anti-mouse Alexa Fluor 594 (for anti-
ED1) or anti-rabbit Alexa Fluor 488 (for anti-iNOS) IgG
antibodies (1:500) for 1 hr at RT. Finally, the cells were
mounted with the DakoCytomation fluorescent medium and
visualized via fluorescence microscopy. Figures 1 and 4 show
representative images of each experimental condition obtained
in three or four independent experiments.
Western Blotting
Treated microglia cells were lysed with ice-cold isola-
tion buffer [250 mM sucrose, 20 mM HEPES, 10 mM KCl,
1.5 mM MgCl2 (pH 7.4), 1 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl fluoride (PMSF), and protease inhibitor
cocktail]. The lysates were rapidly frozen/defrosted three times
and cleared by centrifugation (20,200g for 10 min). The su-
pernatant was collected and assayed for protein content with
the Bio-Rad reagent. The proteins were separated by electro-
phoresis on 10% SDS-PAGE and transferred electrophoreti-
cally to a PVDF membrane (Agostinho and Oliveira, 2003).
To facilitate the identification of proteins, a prestained preci-
sion protein standard (Bio-Rad) was used. iNOS was detected
by immunodetection using a rabbit anti-iNOS monoclonal
antibody (1:500) and an alkaline phosphate-conjugated sec-
ondary antibody (1:20,000). All experiments were repeated in
at least three independent cell preparations. Bands of immuno-
reactive protein were visualized, after membrane incubation
with ECF reagent for 5 min, on a Versadoc image system.
Densities of blot bands were calculated in the Quantity One
program (Bio-Rad).
Fig. 1. Effect of Ab and PrP peptides on microglial morphology. Cul-
tured rat brain microglia cells were treated or not (control) with Ab1–40
(5 lM) or PrP106–126 (25 lM) for 3 hr. LPS (0.1 lg/ml) was used to
treat the cells for the same period, because it is a classical inductor of
inflammation (positive control). Control and treated cells were fixed
and immunostained for ED-1 (microglia activation marker), as de-
scribed in Materials and Methods. The cells were observed in contrast
phase and in fluorescent view on an Axiovert 200 fluorescence micro-
scope. Images were obtained by overlaying phase-contrast and ED-1
fluorescence (red) and are representative of each experimental condi-
tion. The same pattern of images was obtained in three or four inde-
pendent experiments. Scale bars ¼ 20 lm.
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Nitrite Assay
NO production was determined by the nitrite(NO2
–)
assay with the Griess reagent (0.1% N-[1-naphtyl]ethylenedi-
amine dihydrochloride, 1% sulphanilamide and 2% phosphoric
acid). This colorimetric method is based on the measurement
of NO2
–, a stable endproduct of the reaction between NO and
molecular oxygen. After microglial cell incubation with pepti-
des or LPS, culture supernatants and cell lysates (50 ll) were
mixed with an equal volume of Griess reagent for 15 min in
the dark at RT, according to the method described by Huygen
(1970). Absorbance was measured at 550 nm with a micro-
plate reader. The nitrite concentration was determined from a
sodium nitrite standard curve ranging from 0 to 100 lM. All
experiments were performed in duplicate, in four to six inde-
pendent cell preparations. The total nitrite concentration pro-
duced by microglia cells was calculated by adding the nitrites
in cellular supernatant and in cell lysates.
Analysis of Reactive Oxygen Species Production
After microglia treatment with the peptides or LPS, the
ROS production was evaluated through the Amplex red assay
and by using a fluorescent method.
Amplex red assay. The intracellular levels of hydro-
peroxides, mainly H2O2, were measured by using the Amplex
red hydrogen peroxide/peroxidase assay kit. Samples from cell
lysates of microglia treated with peptides or LPS, as well as
standard curve samples, were incubated with a reaction mix-
ture that contains Amplex red reagent (10-acetyl-3,7-dihy-
droxyphenoxazine) and horseradish peroxidase, according to
the manufacturer’s instructions. All experiments were per-
formed in duplicate, in three to six independent cell prepara-
tions. Absorbance was read at 570 nm in a microplate reader.
Fluorimetric DCF method. The levels of intracellu-
lar peroxides were detected with a nonfluorescent compound,
20,70-dichlorofluorescin diacetate (DCFH2-DA), which per-
meates the cells and is desterified by esterases to acid 20,70-
dichlorofluorescin. This ionized acid is trapped in the cells
and can be oxidized to fluorescent 20,70-dichlorofluorescein
(DCF) by hydroperoxides (Cathcart et al., 1983). Microglia
cells cultured in glass coverslips, after being treated with pepti-
des or not, were incubated with 5 lM DCFH2-DA, as
described previously by Agostinho and Oliveira (2003). The
different experimental conditions were repeated in three to six
independent cell preparations. DCF fluorescence was mea-
sured at 502 nm excitation and 550 nm emission and ex-
pressed as arbitrary units.
Cytokine Release Assessment
The levels of interleukin-1b (IL-1b) and IL-6 were
determined in culture supernatants of microglia cells (0.2 3
106 cells/cm2) treated with the peptides or LPS by using
enzyme-linked immunosorbent assay (ELISA) kits specific for
rat IL-1b and IL-6. The samples of culture supernatants, con-
trols, and standards were pipetted into microplates of these
ELISA kits, according to the manufacturer’s instructions
(R&D Systems). The experiments were performed in dupli-
cate, in four to six independent cell preparations. The absorb-
ance of formed products was measured at 450 nm, with the
correction wavelength at 540 nm, in a microplate reader. The
sample values were read off the standard curve and expressed
as picograms per milliliter of cell supernatant.
Neuronal Viability Evaluation
Neuronal death was assessed by fluorescence microscopy
with the fluorescent DNA stain Hoechst 33342. Dead cells
(mainly apoptotic) have fragmented or irregularly stained
chromatin, whereas viable cells display homogeneous staining.
Neurons plated in glass coverslips were incubated for 5 min
with 300 ll of Hoechst 33342 (10 lg/ml) in the dark. After
being washed with PBS, the cells were observed in a fluores-
cence microscope. Those cells showing irregular and relatively
high blue fluorescence (dead cells) were identified from an av-
erage of 300 cells per treatment and cell batch. Each individ-
ual experiment, made in duplicate, was repeated in four differ-
ent cell preparations. The cells were examined by blinded
counting. Four pictures from different fields (selected ran-
domly) were taken from each individual experiment, in which
all the cells (6 300) were counted. Data are expressed as the
percentage of dead cells among the total cells counted.
Statistical Analysis
Results are expressed as means 6 SEM of the number
of experiments indicated in the figure legends. Statistical sig-
nificance was determined by using an analysis of variance
(ANOVA), followed by Dunnett’s posttests, or by using the
two-tailed Student’s t-test (as indicated in Fig. 7).
RESULTS
To characterize the activation of microglia induced
by Ab and PrP, the synthetic peptides Ab1–40, Ab1–42
(the major components of amyloid plaques in AD), and
PrP106–126 (a peptide fragment that mimics PrP
Sc toxicity
and forms fibrils in vitro; Combs et al., 1999) were used
to stimulate cultured rat microglia cells. The scrambled
PrP (PrPscram) and the reverted peptide Ab40–1 were
used in some experiments as negative controls. In addi-
tion, the bacterial endotoxin LPS, a classic inductor of
glial activation in vitro, was used as a positive control.
Studies performed by our group have shown that Ab1–40
and Ab1–42 were added to cultures in a fibrillar form,
which was maintained during the time periods in culture
(Resende et al., personal communication). We have also
observed that PrP106–126 forms fibrils, but its neurotoxic
effects are independent of aggregation state (Melo et al.,
unpublished data). Taking into account preliminary
assays in which the effect of different concentrations
(0.5–5 lM) of each peptide on microglia morphology
and NO production was tested, we used 5 lM Ab1–40,
0.5 lM Ab1–42, or 25 lM PrP106–126. These concentra-
tions induced significant microglia activation (data not
shown).
Morphological Alterations of Microglia
The morphological changes of microglia induced
by Ab and PrP peptides were visualized through phase-
contrast microscopy and by assessing the immunoreactiv-
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ity to anti-ED-1 antibody, which binds to ED-1 recep-
tor (also designated CD68) of activated microglia with
high affinity (Eikelenboom et al., 2002). As can be
observed in Figure 1, the synthetic peptides Ab1–40 and
PrP106–126 induced changes in shape and size of micro-
glia cells, compared with untreated cells (control). LPS
also caused alterations in microglial morphology. Micro-
glial cells treated with Ab1–40 (5 lM), PrP106–126
(25 lM), or LPS (0.1 lg/ml) for 3 hr have a rounded,
ameboid morphology, have phase-bright cell soma, and
exhibit small and thick branches. A similar pattern of
morphologic alterations was observed in microglia
treated with 0.5 lM Ab1–42 (data not shown). Control
cells have an elongated shape and ramified cell bodies.
Moreover, it was observed that microglia treated with
peptides crowd together and form clusters, whereas con-
trol cells were dispersed. An intense immunoreactivity
against ED-1 (red fluorescence) was also observed in
microglia treated with peptides or LPS, compared with
control cells (Fig. 1), indicating that morphological alter-
ations induced by Ab and PrP peptides are a sign of
microglia activation. These morphologic and immuno-
phenotypic alterations became evident upon 3 hr of
treatment with peptides and LPS and were maintained
for at least 24 hr (data not shown). The effect of PBS
(2.1%) was also tested on microglia morphology. PBS-
treated cells (vehicle control) exhibit a ramified mor-
phology and low ED-1 immunoreactivity, similar to
untreated cells (data not shown).
Microglia Molecular Responses
Since microglial activation also involves functional
alterations, we further investigated whether Ab and PrP
peptides affect the production and/or release of some
inflammatory and neurotoxic factors.
Reactive nitrogen and oxygen species produc-
tion. Figure 2 shows the levels of NO produced by
cultured microglia cells treated with Ab and PrP pepti-
des for different incubation times. The levels of NO in
microglia treated with Ab1–40 (1.28 6 0.10 lM/lg pro-
tein), Ab1–42 (1.12 6 0.08 lM/lg protein), and PrP106–126
(1.65 6 0.20 lM/lg protein) for 3 hr were higher than,
but not significantly different (P > 0.05) from, those ob-
served in control cells (1.05 6 0.26 lM/lg protein).
However, at 6 hr of incubation, these peptides caused a
Fig. 2. Nitric oxide (NO) production by microglial cells treated with
Ab and PrP peptides. Cultured microglia cells were treated or not
(control) with Ab1–40 (5 lM), Ab1–42 (0.5 lM), and PrP106–126
(25 lM) for 3, 6, 12, and 24 hr. The effects of reverted Ab1–40
sequence, Ab40–1 (5 lM), scrambled PrP106–126 (PrPscram, 25 lM),
and LPS (0.1 lg/ml) are also shown. Untreated cells (control) and
cells treated with 2.1% PBS (vehicle control) were used as controls.
The concentration of nitrite, a stable NO product, was determined
by the Griess assay. Values represent the total concentration of nitrite,
determined in cell lysates and culture supernatants, expressed as lM/
lg protein. Data are means 6 SEM of four to six independent
experiments. *P < 0.05, ***P < 0.001, significantly different from
control cells under the same experimental conditions.
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significant (P < 0.05) increase of about 50% in the levels
of NO produced compared with untreated cells (control)
or PBS-treated cells (vehicle control). For longer periods
of incubation, 12 hr and 24 hr, no significant differences
were observed between NO produced by Ab- or PrP-
treated cells and by controls (untreated and PBS treated).
At 6 hr of incubation with Ab1–40 and PrP106–126, we
was observed a significant increase in the amount of NO
produced by microglia, so we analyzed whether the
reverse sequence of Ab, Ab40–1, and the scrambled
PrP106–126 peptide (PrPscram) affected NO production. In
the presence of these peptides, which are not neurotoxic
(Agostinho and Oliveira, 2003), the levels of NO pro-
duced were similar to the level determined in control
cells, suggesting that microglia molecular responses trig-
gered by Ab1–40 and PrP106–126 were specific for these
amino acid sequences. The effect of Ab1–42 (0.5 lM) in
NO production was similar to that obtained with Ab1–40
(5 lM), at all incubation times studied (Fig. 2); there-
fore, in the following experiments, we used the smallest
peptide. The effect of LPS (0.1 lg/ml) on NO produc-
tion by microglia was also evaluated and, as expected, it
was observed that this toxin significantly (P < 0.001)
increased NO levels (Fig. 2).
To determine whether the increase in NO produc-
tion caused by Ab and PrP peptides was correlated with
alterations in iNOS expression, we determined the levels
of this protein in control cells and in cells treated with
Ab1–40 (5 lM) or PrP106–126 (25 lM). We analyzed the
levels of iNOS at 6 hr of incubation, because an increase
in NO production at this incubation time was observed.
The results obtained via immunoblotting showed that
iNOS levels in microglia treated with Ab1–40 (1.46 6
0.03 a.u.) or PrP106–126 (1.58 6 0.05 a.u.) were signifi-
cantly (P < 0.05) higher than those determined in con-
trol cells (1.04 6 0.02 a.u). LPS (0.1 lg/ml) also aug-
mented (P < 0.01) iNOS levels (Fig. 3). To provide
additional evidence that Ab and PrP peptides affect the
expression of iNOS, immunocytochemistry studies were
performed to visualize the iNOS expression in cells
treated with those peptides. As can be seen in Figure 4,
the anti-iNOS fluorescence labelling (green) was more
intense in cells treated with Ab1–40, PrP106–126, or LPS
than in control cells. The images of differential interfer-
ence contrast (DIC) are also displayed (Fig. 4) to show
that, under control conditions, the number of cells
labelled with the anti-iNOS antibody was lower than
that in cells treated with the peptides or LPS. These data
support those obtained from immunoblotting (Fig. 3),
showing that Ab and PrP peptides augmented iNOS
expression. This increase in iNOS expression can explain
the rise in NO production observed in microglia treated
with these amyloidogenic peptides (Fig. 2).
Microglial activation may involve the production
of ROS that can react with NO forming others reactive
nitrogen species (Andersen, 2004). To examine whether
Ab1–40 and PrP106–126 peptides trigger ROS production
in microglia cells, we determined the intracellular hydro-
peroxides levels. By using the Amplex red assay, we
measured the hydroperoxides levels in cell lysates of mi-
croglia treated with the peptides or LPS (Fig. 5A). The
levels of ROS in microglia treated with Ab1–40 (16.4 6
1.4 lM/lg protein) and PrP106–126 (16.6 6 3.0 lM/lg
protein), for 3 hr, was higher than that determined in
untreated cells (11.2 6 0.8 lM/lg protein). PBS (2.1%)
was without effect on ROS production (data not
shown). This significant increase in ROS levels (about
46%) was similar to that determined in microglia treated
with Ab1–40 or PrP106–126 for 6 hr (50% 6 2%) and 12 hr
(48% 6 2%) compared with control cells (data not shown).
A significant (P < 0.01) enhancement in ROS levels
was also observed in cells treated with LPS (Fig. 5A). A
3-hr incubation with Ab1–40 and PrP106–126 significantly
enhanced ROS, so we monitored the ROS production
in living microglia cells treated with peptides for this pe-
riod. As can be seen in Figure 5B, the ROS levels produced
by microglia cells treated with Ab1–40 or PrP106–126 were
significantly (P < 0.01) higher than those formed in the
absence of peptides. These data are in agreement with
those obtained from the Amplex red assay and suggest
Fig. 3. Effect of Ab and PrP peptides on inducible NO synthase
(iNOS) expression. Microglia cells were treated or not (control) with
Ab1–40 (5 lM), PrP106–126 (25 lM), and LPS (0.1 lg/ml) for 6 hr.
Cell lysates were examined by immunoblotting with an anti-iNOS
(130 kDa) monoclonal antibody, as described in Materials and Meth-
ods. The blot was stripped and reprobed with antiactin antibody
(clone C4; Chemicon) to estimate the total amount of protein loaded
in gel. Immunoreactive bands were visualized by scanning on a Ver-
sadoc Image system, and the levels of proteins were quantified in the
Quantity One program. Bars represent the relative levels of iNOS,
compared with actin, and were expressed as arbitrary units. Data are
the means 6 SEM of three independent experiments. Representative
blots of iNOS and actin are shown. *P < 0.05, **P < 0.01, signifi-
cantly different from control cells.
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Fig. 4. Representative images of iNOS expression in microglial cells
treated with Ab and PrP peptides. The cells were incubated with
Ab1–40 (5 lM), PrP106–126 (25 lM), and LPS (0.1 lg/ml) for 4 hr.
Control cells and treated cells were immunostained with anti-iNOS
(green) antibody, as described in Materials and Methods, and
observed in fluorescent view (right column) and in differential inter-
ference contrast (DIC, left column) on an Axioskop 2 plus fluores-
cence microscope. The same pattern of labelling was obtained in
three or four independent experiments. Scale bars ¼ 20 lm.
that Ab and PrP peptides triggered ROS production in
microglia.
Cytokine secretion. In Alzheimer’s and prion
diseases cytokines are thought to promote Ab and PrP
neurotoxicity (Hanisch, 2002; Hoozemans et al., 2002;
Nelson et al., 2002). Therefore, we analyzed whether
Ab1–40 and PrP106–126 peptides affect the secretion of
interleukin-1b (IL-1b) and interleukin 6 (IL-6) by
microglia cells. The levels of these cytokines were
measured in culture supernatants of microglia treated
with the peptides for 3, 6, 12, and 24 hr (Fig. 6). Ab1–40
increased IL-6 secretion significantly (P < 0.01) after
12 hr of incubation, whereas PrP106–126 raised the
secretion of this cytokine at an early phase. Indeed, as
can be seen in Figure 6A, cells treated with PrP106–126
for 3–6 hr secreted significantly (P < 0.05) more IL-6
than under control conditions or even after Ab1–40
treatment. However, at 12 hr of incubation either
Ab1–40 or PrP106–126 increased the IL-6 secretion by
about 170% or 90% (above control values), respec-
tively. These data suggest that Ab1–40 is more efficient
in inducing IL-6 secretion than PrP106–126. The levels
of IL-6 secreted by microglia treated with Ab1–40 or
PrP106–126 for 12 hr were not significantly different
from those determined at 24 hr of incubation, indicat-
ing that IL-6 secretion reached a plateau upon 12 hr of
incubation with the peptides. The effect of Ab1–42
(0.5 lM) on IL-6 secretion was also evaluated for 3, 6,
12, and 24 hr. Similarly to what was observed with Ab1–40,
Ab1–42 caused a significant increase in IL-6 secretion
only after 12 hr of incubation, the amounts of cytokine
released at 12 hr and 24 hr being 380.5 6 12.7 pg/ml
and 367.2 6 30.0 pg/ml, respectively. LPS significantly
increased IL-6 secretion for all incubation times studied
(Fig. 6A).
Figure 6B shows that IL-1b secretion was not sig-
nificantly affected by Ab1–40, whereas PrP106–126 caused
a significant (P < 0.05) increase in the release of IL-1b
at 6 hr of incubation. This enhancement in IL-1b secre-
tion was maintained for longer incubation periods (12–
24 hr). The levels of IL-1b secreted by microglia treated
with Ab1–40 for 48 hr were also determined, but no sig-
nificant augmentation was observed (data not shown),
suggesting that this peptide was not able to trigger IL-1b
secretion. Likewise, Ab1–42 (0.5 lM), tested for 3–24 hr,
did not significantly (P > 0.05) affect IL-1b release
compared with control cells (data not shown). Similarly
to what was observed for NO and ROS production,
PBS (2.1%, vehicle control) did not affect IL-1b or IL-6
secretion (data not shown). Taken together, these results
indicate that Ab1–40 and PrP106–126 affected microglial
cytokines secretion in a distinct manner.
Fig. 5. Effect of Ab and PrP peptides on reactive oxygen species
(ROS) levels produced by microglia cells. The intracellular ROS lev-
els, mainly hydroperoxides, of microglial cells treated or not (control)
with Ab1–40 (5 lM), PrP106–126 (25 lM), and LPS (0.1 lg/ml) were
determined by using the Amplex red assay (A) and the fluorescent
probe DCF (B). Cultured microglia cells were incubated with the
peptides or with LPS (positive control) for 6 hr. The quantification
of ROS levels by the Amplex red assay was performed in cellular
lysates. The fluorescent probe DCF monitored (for 30 min) the pro-
duction of ROS in living microglia cells (see Materials and Methods).
The ROS levels, measured by the Amplex red (A), were expressed as
lM/lg protein and by arbitrary units of DCF fluorescence (B). Data
are means 6 SEM of three to six independent experiments. *P <
0.05, **P < 0.01, significantly different from control cells under the
same experimental conditions.
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Neurodegeneration Caused by Microglia
Activated by Ab and PrP Peptides
To evaluate whether the substances released by Ab-
or PrP-activated microglia cause neuronal death, we used
cocultures of microglia-neurons (Mic-Neu). Ab1–40
(5 lM), PrP106–126 (25 lM), or LPS (0.1 lg/ml) was
added to culture plate inserts containing microglia cells.
In these cocultures, the substances released by microglia
can reach neurons by diffusing through the membrane
porous (0.4 lm) of inserts. Figure 7 shows that, in cocul-
tures treated with Ab1–40, PrP106–126, or LPS, the per-
centage of dead neurons was significantly (P < 0.01)
higher than in untreated cocultures (control). These data
suggest that the substances released by Ab-, PrP-, or LPS-
activated microglia triggered neuronal death. Because we
observed that microglial secretion of IL-6, but not of IL-
1b, was significantly augmented by Ab and PrP treatments,
the effect of a neutralizing antibody for IL-6 was eval-
uated in cocultures. With the presence of the antibody
(50 ng/ml), we observed a significant (P < 0.05) reduc-
tion (about 40%) of neuronal death after microglia treat-
ment with Ab or PrP. The anti-IL-6 antibody also sig-
nificantly (P < 0.05) prevented the neuronal death
induced by LPS-treated microglia (Fig. 7, Mic-Neu þ
anti-IL-6). Similar effects were observed with 100 ng/ml
anti-IL-6 antibody (data not shown). Because in these
cocultures systems the peptides can diffuse through po-
rous membrane, we determined whether Ab1–40, PrP106–126,
and LPS added to inserts without microglia affect neuro-
nal viability (Fig. 7, Neu). When the inserts without
microglia cells were used, the Ab1–40 and PrP106–126, but
not LPS, caused significant (P < 0.05) neuronal injury.
Although neuronal death in cocultures (Mic-Neu) could
be partially due to a direct effect of the peptides on neu-
Fig. 7. Neuronal death induced by Ab- and PrP-activated microglia
in the presence or absence of a neutralizing antibody for IL-6. Ab1–40
(5 lM), PrP106–126 (25 lM), or LPS (0.1 lg/ml) was added into in-
serts containing microglia cells that were cocultured with cortical
neurons (Mic-Neu), for 24 hr. When the effect of anti-IL-6 antibody
was tested in these cocultures system (Mic-Neu þ anti-IL-6), 50 ng/ml
of antibody was added to neuronal cultures just prior the treatment
of microglia (in inserts) with the peptides or LPS. A similar system
using inserts without cells, which were placed in wells containing
the cultured neurons (Neu), was also used to determine the direct
effect of peptides on neuronal viability (see Results). After incuba-
tion with the peptides or LPS in the presence or absence of anti-
IL-6, inserts were removed, and the neuronal cells were labelled
with Hoechst 33342. The number of dead and viable cells was
determined, analyzing the nuclear morphology. Data are expressed
as a percentage of dead cells relative to the total number of cells
counted (6300 cells per treatment and cell batch) and are means 6
SEM of four independent experiments. *P < 0.05, **P < 0.01, sig-
nificantly different from control cells under the same experimental
conditions (Mic-Neu, Mic-Neu þ anti-IL-6, or Neu); þP < 0.05
compared with cells treated with the same peptide or LPS in the
presence of anti-IL-6 antibody (two-tailed Student’s t-test).
Fig. 6. Cytokines produced by microglia treated with Ab or PrP
peptides. The cells were treated with Ab1–40 (5 lM), PrP106–126
(25 lM), or LPS (0.1 lg/ml) for 3, 6, 12, and 24 hr. The levels of
interleukin-6 (A) and interleukin-1b (B), in control cells and in cells
treated with the peptides or LPS, were determined in culture super-
natants by ELISA, as described in Materials and Methods. The
amount of cytokines released is expressed as pg/ml cell supernatant.
Data are means 6 SEM of four to six independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001, significantly different from
control cells under the same experimental conditions.
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rons, the data suggest that IL-6 released by microglia
treated with Ab1–40, PrP106–126, or LPS triggered neuro-
degeneration.
DISCUSSION
Several studies have reported that Ab and PrP syn-
thetic peptides induce microglia activation in biological
models containing neurons and/or astrocytes. In these
cell systems, the activation of microglia is influenced not
only by the peptides but also via substances released by
injured cells (Eikelenboom et al., 2002; Eskes et al.,
2003). In this study, we used pure cultures of rat brain
microglia cells to investigate whether Ab and PrP syn-
thetic peptides, per se, differentially activate these immu-
noeffector cells. The microglia culture system used, de-
spite being maintained in astrocyte-conditioned media,
did not include reactive astrocytes or the multitude of
other cytokines and factors released by them that cer-
tainly contribute to trigger neurodegeneration (von
Bernhardi and Eugenı´n, 2004; Schultz et al., 2004).
Moreover, the effect of substances released by Ab- and
PrP-activated microglia cells in neuronal viability was
also evaluated by using cocultures, where neurons can
be separated before cell death analysis. Therefore, this
defined cell system can be useful in identifying initial
and specific targets that might contribute to the develop-
ment of therapeutic strategies to treat AD and PRE.
Microglia activation involves multiple pathways
that result in morphological alterations, proliferation,
changes in phagocytic competence, and production of
bioactive molecules, which can modulate a large spec-
trum of functional activities (Streit et al., 1999). In this
study, we observed that cultured rat brain microglia cells
exposed to Ab1–40 or PrP106–126 underwent considerable
changes in morphology and ED-1 immunoreactivity in a
time-dependent manner, with the alterations starting to
be evident after 3 hr treatment. The morphological and
immunophenotypical alterations of microglia induced by
these peptides were similar to those observed in cells
treated with LPS, a strong inductor of glial activation in
vitro (Fig. 1). These data suggest that Ab and PrP syn-
thetic peptides induced changes in microglia morphology
that are correlated with the activation process.
The substances released by activated microglia have
been pointed out as essential elements in the onset and
progression of neurodegenerative diseases, such as AD
and PRE (Streit, 2002; Nelson et al., 2002; Liu and
Hong, 2003). NO can be an important signalling mole-
cule; however, when it reacts with superoxide, it can
form peroxynitrite that might act as a neurotoxic factor
(Fabrizi et al., 2001; Xie et al., 2002; Liu and Hong,
2003). Our results show that Ab1–40, Ab1–42, and
PrP106–126 caused a significant peak in microglial NO
production, at 6 hr incubation, whereas LPS induced a
huge increase in NO levels that was maintained for all
incubation periods tested. Under our experimental con-
ditions, the increases in NO production induced by Ab
and PrP peptides were accompanied by an increase in
ROS levels, mainly hydroperoxides. Indeed, by using
two different assays (DCF and Amplex red), a significant
increase was observed in microglial ROS production, at
a relatively early phase of peptide exposure (3–6 hr). Xie
and colleagues (2002) reported that peroxynitrite is the
major mediator of the neurotoxicity induced by Ab-
and LPS-activated microglia cells. The brains of AD
patients exhibit high levels of nitrotyrosine, which result
from the reaction of peroxynitrite with tyrosine residues
of proteins (Smith et al., 1997), suggesting a participation
of NO and ROS in this disorder. Moreover, ROS can
promote the aggregation of amyloid fragments and con-
sequently the formation of amyloid deposits (Van Ever-
broeck et al., 2004). Therefore, the early release of NO
and ROS may be an essential factor in AD and PRE
progression.
It is known that stressful conditions can trigger the
expression of iNOS, which can generate NO from L-
arginine (Vallance and Leiper, 2002). We observed that
Ab1–40 and PrP106–126, after 6 hr incubation, significantly
increased the iNOS levels of microglia. Accordingly,
other studies have reported that Ab and PrP synthetic
peptides induce iNOS expression, by measuring the lev-
els of mRNA and/or of protein (Fabrizi et al., 2001;
von Bernhardi and Eugenı´n, 2004), and it was also stated
that iNOS expression is increased in the brains of PrPSc-
infected animals (Ju et al., 1998; Williams et al., 1997)
and of AD patients (Luth et al., 2002). A great variability
in the incubation time with peptides needed to induce
changes in iNOS expression and NO production has
been reported in different studies. These discrepancies
probably are due to experimental conditions used, such
as the presence of astrocytes or neurons, source (human,
rat, mouse) of microglia cells, culture age and density, as
well as culture media composition. Indeed, a recent
study stated that Ab peptides induce higher increases in
iNOS levels and NO production in pure microglia cul-
tures than in mixed glial cell cultures (von Bernhardi
and Eugenı´n, 2004).
Cytokines are signalling proteins that are thought
to participate in several events in CNS, such as immu-
noregulation, intercellular communication, and neurode-
velopment. IL-1b and IL-6 are important effector cyto-
kines, acting as immunostimulatory and proinflammatory
factors (Hanisch, 2002). Both these cytokines have been
identified in amyloid plaques, near activated microglia,
and it is widely suggested that they play an important
role in neurodegeneration (Hanisch, 2002; Hoozemans
et al., 2002; Nelson et al., 2002). Our data show that
PrP106–126, but not Ab1–40, augmented the IL-1b secre-
tion by microglia. Moreover, it was observed that IL-6
secretion was induced only by PrP106–126 at an early
phase (3–6 hr), but Ab1–40 was more efficient than
PrP106–126 for longer incubation periods, inducing a
higher production of this cytokine. In accordance with
our results, it was shown that PrP106–126 induces IL-6
and IL-1b release in cultured mouse microglia (Peyrin
et al., 1999; Veerhuis et al., 2002), and fibrillar Ab is
unable to induce IL-1 (b and a) release (Li et al., 2004).
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On the contrary, it was reported that Ab25–35 peptide
(without fibrillogenic capacity) treatment for 24 hr indu-
ces the release of IL-1b but not of IL-6 (Lee et al.,
2002). Recent studies have reported that the activation
of human microglia and the consequent release of cyto-
kines induced by Ab and PrP are increased by comple-
ment factors C1q and serum amyloid P, which are usu-
ally associated with amyloid deposits in AD and PRE
(Veerhuis et al., 2003, 2005). Our data suggest that
microglia cells react differentially to Ab and PrP peptides
in IL-1b and IL-6 secretion. The differences between
Ab- and PrP-evoked IL-1b and IL-6 release and the
LPS-evoked release are remarkable, probably because
peptides induce subtoxic responses, whereas the endo-
toxin caused an unusual and toxic response. In a paper
by Combs and colleagues (1999), comparing microglia
responses to Ab25–35 and PrP106–126, it was reported that
both peptides activate identical tyrosine kinase-depend-
ent inflammatory signal transduction cascades that lead to
production of neurotoxic substances. These signal path-
ways are also activated by classical immune stimulus of
inflammation, and their primary downstream targets are
transcription factors that positively modulate the expres-
sion of proinflammatory factors (Combs et al., 1999,
2000). Our data reinforce these findings, in that we
observed that microglia cells were similarly affected by
Ab and PrP peptides as concerns ROS and NO produc-
tion as well as levels of iNOS expression.
Activated microglia secrete a wide range of sub-
stances, including, in addition to those already men-
tioned, various neurotoxic factors that could represent
the outcome of a coordinated program of intracellular
signalling events mediating proinflammatory and neuro-
toxic responses (Fabrizi et al., 2001; Hanisch, 2002). By
uing cocultures of microglia-neurons, we have observed
that substances released by microglia treated with Ab1–40
and PrP106–126, as well as with LPS, caused neuronal
injury. The blockade of IL-6 physiological effects, by
using a neutralizing anti-IL-6 antibody, significantly pre-
vented the neurodegeneration caused by Ab-, PrP-, and
LPS-activated microglia. In accordance with these
results, several groups have reported that IL-6 exposure
compromises neuronal viability (Qiu et al., 1998; Nelson
et al., 2004). On the other hand, it was also stated that
this cytokine can be neuroprotective and neurotrophic
in several pathological conditions (Carlson et al., 1999;
Hanisch, 2002; Peng et al., 2005). Indeed, the tendency
of IL-6 for a proinflammatory or an antiinflammatory
effect is probably determined by its concentration and
the simultaneous presence of other factors, such as cyto-
kines. We can speculate that IL-1b was not involved in
the neurotoxicity triggered by activated microglia
because IL-1b secretion increased only after PrP or LPS
treatments and not in Ab-activated microglia, although
the extent of neuronal death was similar in cocultures
treated with Ab, PrP, or LPS. Although the data suggest
that IL-6 released by microglia treated with Ab1–40,
PrP106–126, or LPS triggered neurodegeneration, the
neuronal death in cocultures could be due partially to
peptide diffusion through the porous membrane of
inserts, resulting in a direct effect on neurons (see results
obtained when peptides and LPS were added to the
insert without microglia; Fig. 7, Neu). In accordance,
previous reports from our group and others show that
Ab and PrP peptides are neurotoxic (Combs et al.,
1999; Agostinho and Oliveira, 2003).
In conclusion, our data show that Ab and PrP pep-
tides, per se, induced microglia activation and increased
the production of ROS and NO as well as of iNOS
expression. However, these peptides seemed to have a
different time lag in inducing IL-6 release and dissimilar
effects on IL-1b secretion, indicating that Ab and PrP
differentially affect cytokines secretion by microglia. The
IL-6 released by activated microglia contributes to neu-
rodegeneration. Thus, pharmacological interventions tar-
geting prevention of IL-6 secretion and/or its cellular
effects can be useful in treating AD and PRE.
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